News

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis.

HCPLive spoke with Kane about new phase 2 data showing that an oral benzamide provides a significant change from baseline in CGI-S scores for participants with acute schizophrenia.

Phase 4 trial results showed switching to BSV after long-term TDF was noninferior for antiviral efficacy and led to improved kidney function and bone density.

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

Herzig discussed special considerations for treating pain in people with OUD.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Gelles discussed potential concerns with AI’s use in reducing administrative burden but stressed its promise.

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.

Despite no direct correlation being identified, this research highlights a potential association between the two conditions.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

These data highlight the potential impacts of baricitinib across significant hair-bearing areas involved in alopecia areata.

Vega discussed recent efforts in the public health field and his own center that have helped to improve screening rates.

Most patients preferred OLC over their previous phosphate binder, and pill number and size were identified as barriers to phosphate binder adherence.

Tailor discusses the future of AI in ophthalmology and beyond, and some of the challenges it may bring.

Laine gave an overview of the ACP Internal Medicine’s Friday Plenary session and how it reflects top-of-mind topics for IM clinicians.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.

This retrospective, real-world analysis highlights several notable findings on JAK inhibitor use among patients with alopecia areata.

Electronic health interventions improved medication adherence in kidney transplant recipients, with potential implications for improving patient outcomes.

Herzig outlined a talk she gave at the ACP Internal Medicine 2025 meeting reviewing the latest data in acute inpatient pain management.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

In this interview, Chovatiya highlighted the unmet needs of patients with atopic dermatitis and the ways in which nemolizumab’s FDA approval addresses them.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.